Erin Harris

Cell & Gene: The Podcast

Science EN ↓ 151 episodes

Cell & Gene, the most valuable online resource for delivering in-depth content from authoritative authors and sources to professionals in the CGT sector, introduces Cell & Gene: The Podcast. In each episode, Cell & Gene Chief Editor, Erin Harris, will talk to industry and academic leaders about their current initiatives and how they are moving the sector forward.

Be sure to visit the podcast's website and support the creator: www.buzzsprout.com

Author

Erin Harris

Category

Science

Podcast website

www.buzzsprout.com

Latest episode

Nov 19, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Targeting Oncogenic Drivers for Solid Tumor Cancers with Affini-T Therapeutics' Dr. Jak Knowles 25.05.2023

We love to hear from our listeners. Send us a message. Affini-T Therapeutics combines a validated TCR discovery platform with synthetic biology switches to attack tumor biology at its root cause. Co-Founder, CEO, and President Dr. Jak Knowles joins Cell & Gene: The Podcast Host Erin Harris to discuss how the company engineers immune cells to target oncogenic driver mutations, such as KRAS, the...

TJU's Jefferson Institute for Bioprocessing's Impact on CGT with Parviz Shamlou 11.05.2023

We love to hear from our listeners. Send us a message. Parviz Shamlou, Vice President and Executive Director at Thomas Jefferson University joins Cell & Gene: The Podcast to talk to Host Erin Harris about Jefferson Institute for Bioprocessing (JIB), the full-service development and training organization specializing in biopharmaceuticals and biologics. Shamlou explains how JIB will move forwar...

Computational Biology's Role In Gene Therapy With Kriya Therapeutics' Dr. Shankar Ramaswamy 27.04.2023

We love to hear from our listeners. Send us a message. Shankar Ramaswamy, M.D., CEO & Co-Founder, Kriya Therapeutics joins Cell & Gene: The Podcast's Erin Harris for a discussion on the evolving role computational biology plays in gene therapy development. They also discuss the company's lessons learned from building its own North Carolina-based in-house manufacturing facility as...

The Near-Term Future of Exosome Science with Capricor Therapeutics' Dr. Linda Marbán 13.04.2023

We love to hear from our listeners. Send us a message. Dr. Linda Marbán, Ph. D., CEO of Capricor Therapeutics, a clinical-stage biotech focused on the development of cell and exosome-based therapeutics for the treatment and prevention of serious diseases, joins Cell & Gene: The Podcast's Erin Harris to discuss the current state and the near-term future of exosomes. Marbán discusses Capric...

Inside the World's First-Ever Allogeneic Approval with Atara Biotherapeutics' Pascal Touchon 30.03.2023

We love to hear from our listeners. Send us a message. In December 2022, Atara Biotherapeutics’ Ebvallo received European Commission approval as the first-ever therapy for adults and children with EBV+ PTLD. The ground-breaking approval represents the first approval of an allogeneic T-cell immunotherapy ever, globally. Atara Bio's CEO, Pascal Touchon, talks to Cell & Gene: The Podcast&apo...

The Potential of RNA Exon Editing with Ascidian Therapeutics' Romesh Subramanian, Ph.D. 16.03.2023

We love to hear from our listeners. Send us a message. Cell & Gene: The Podcast Host, Erin Harris, welcomes Romesh Subramanian, Ph. D., CEO of Ascidian Therapeutics, a Boston-based biotech focused on rewriting RNA to the pod. During the episode, Subramanian defines RNA exon editing, and they discuss the differences between RNA exon editing and gene editing. With current programs in ophthalmolo...

Automating Processes to Scale CGT Manufacturing with PA Consulting's Paolo Siciliano 02.03.2023

We love to hear from our listeners. Send us a message. When it comes to manufacturing, many cell and gene therapy companies struggle to automate the diverse processes needed to scale manufacturing. London-based PA Consulting's Associate Partner, Paolo Siciliano, talks to Cell & Gene: The Podcast's Erin Harris about how lean, small biotechs with limited resources and limited funds can...

The Why Behind In-House Manufacturing With Sangamo's Andy Ramelmeier 16.02.2023

We love to hear from our listeners. Send us a message. On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Andy Ramelmeir, EVP Head of Technical Operations at Sangamo Therapeutics, a biotech based in Brisbane, California that applies cell and gene therapy to combat Hemophilia A and other genetic diseases. Ramelmeir explains the why behind the company's decision to build...

2023 Market Outlook with AdBio and ISCT's Miguel Forte 02.02.2023

We love to hear from our listeners. Send us a message. Miguel Forte is Entrepreneur in Residence at AdBio, a VC firm based in France, and President Elect of ISCT. Forte and Cell & Gene: The Podcast host, Erin Harris, break down market outlook perspective for the cell and gene therapy space. He provides valuable tips to employ when seeking VC partnership, and he covers ISCT's primary focus...

CMC and Scale Up with Mustang Bio's Robert Sexton 19.01.2023

We love to hear from our listeners. Send us a message. MustangBio's Robert Sexton, VP Program and Alliance Leadership, explains the why behind the need for this role in any CGT company. Having worked for Novartis, Sanofi, Legend Biotech, and more, with responsibilities having included quality, operations, and order management, Sexton is currently responsible for aspects of CMC. As such, he ad...

An Interview with Dr. Peter Marks 05.01.2023

We love to hear from our listeners. Send us a message. Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER) within the Food and Drug Administration (FDA) sits down with Cell & Gene: The Podcast host Erin Harris to discuss the most anticipated areas of innovation in clinical development, and he offers recommendations to companies in their engagement with the FDA...

Inside NK and Macrophage Cellular Immunotherapies with Shoreline Biosciences CSO Dr. Robert Hollingsworth 22.12.2022

We love to hear from our listeners. Send us a message. Shoreline Biosciences' Chief Scientific Officer Dr. Robert Hollingsworth shares his insight on intelligently designed allogeneic off-the-shelf, standardized, and targeted iPSC-derived natural killers (NK) and macrophage cellular immunotherapies. He explains the company's preclinical testing on a potential NK cell therapy for acute my...

The Future of iPSCs with BlueRock Therapeutics' CEO Seth Ettenberg 08.12.2022

We love to hear from our listeners. Send us a message. BlueRock Therapeutics' President and CEO Seth Ettenberg, Ph. D. talks to Cell & Gene: The Podcast listeners about the company's Phase 1 Clinical Trial for Advanced Parkinson’s Disease. Ettenberg also covers the most promising therapeutic applications for iPSCs currently in development as well as the major regulatory challenges th...

Manufacturing at the Point of Care with Orgenesis' CEO Vered Caplan 24.11.2022

We love to hear from our listeners. Send us a message. Orgenesis' CEO, Vered Caplan explains the business model behind providing cell and gene therapies that may be manufactured at the point of care. She details how working with hospitals and healthcare providers to enable them to participate in CGT development on their sites and providing these therapies in-house by adapting them to closed s...

Capstan Therapeutics' CEO Laura Shawver on In Vivo Cell Engineering 10.11.2022

We love to hear from our listeners. Send us a message. Capstan Therapeutics' CEO, Laura Shawver, Ph. D., talks us through the company's in vivo CAR therapies and what led to the in vivo cell engineering breakthrough that has been decades in the making. Shawver explains the promise of harnessing mRNA and targeted LNP delivery to train a patient’s body to make CAR-T cells in vivo. She also...

PepGen's SVP Head Of Clinical Development On Delivery Of Oligonucleotide Therapies 27.10.2022

We love to hear from our listeners. Send us a message. PepGen, a Cambridge, MA-based biotech, is advancing oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases has focused on delivery. SVP Head of Clinical Development Dr. Michelle Mellion explains PepGen's trial of PGN-EDO51, the company’s lead product candidate for the treat...

BridgeBio's Chief Regulatory Affairs Officer Adora Ndu on PDUFA VII Reauthorization 13.10.2022

We love to hear from our listeners. Send us a message. On the heels of Congress' reauthorization of the Prescription Drug User Fee Authorization (PDUFA) Act, BridgeBio's Chief Regulatory Affairs Officer, Adora Ndu, explains the Commitment Letter, the programs that may be rolled out under PDUFA VII, why right-sizing CBER will help the cell and gene sector going forward as well as how spon...

Inside RNAi with Arrowhead Pharmaceuticals' Javier San Martin 29.09.2022

We love to hear from our listeners. Send us a message. Arrowhead Pharmaceuticals is a biopharmaceutical company based in Pasadena, CA that develops medicines that treat intractable diseases by silencing the genes that cause them. Javier San Martin, Arrowhead's CMO, talks to Cell & Gene: The Podcast listeners about the similarities and differences between RNAi and CRISPR. He also explains...

Planning For Manufacturing Capacity With Kite Pharma's Will Junker 15.09.2022

We love to hear from our listeners. Send us a message. Will Junker, Head of Manufacturing Quality at Kite Pharma, talks to Cell & Gene: The Podcast listeners about the challenges associated with capacity planning, whether to partner with a CDMO, and why it's important to prioritize inventory over time-to-market. We also discuss why developing a better understanding of the vector manufactu...

Commercialization Learnings with Novartis Gene Therapies' President Chris Fox 01.09.2022

We love to hear from our listeners. Send us a message. With 20+ gene therapy targets in Novartis Gene Therapies’ pipeline, President Chris Fox and her team are hyper-focused on newborn screenings as the pathway to helping more and more patients. The company's initial gene therapy, Zolgensma, for spinal muscular atrophy (SMA) has been approved in more than 40 regions and countries and has been...

A Stem Cell-Derived Treatment for T1D 18.08.2022

We love to hear from our listeners. Send us a message. Sernova Corp. is a clinical-stage regenerative therapies company currently focused on insulin-dependent diabetes. CEO and President, Philip Toleikis, Ph. D., details the company's on-going clinical trial to treat Type 1 diabetes (T1D) as well as the very real potential to progress from simply masking symptoms to having a functional cure f...

Best Practices for Partnering with a CDMO 04.08.2022

We love to hear from our listeners. Send us a message. Emily Moran, VP of Vector Manufacturing and Avi Nandi, VP of Process Development at the Center for Breakthrough Medicines share key considerations for biotechs looking to partner with a CDMO. During this epsiode, biotechs will learn how to reduce risk, lower costs, and how to better manage expectations when it comes the biotech / CDMO relation...

An Interview with Dr. Carl June 21.07.2022

We love to hear from our listeners. Send us a message. Dr. Carl June, an HIV gene therapy pioneer and the father of CAR-T cell therapy, joins Cell & Gene: The Podcast to discuss the current state of CAR-T therapy, what's on the short-term horizon for immunotherapy, on-going manufacturing capacity issues, an update on Emily Whitehead, the first child to receive CAR-T cell therapy on an exp...

Inside Gamma Delta T Cells with TC BioPharm’s CEO, Bryan Kobel 07.07.2022

We love to hear from our listeners. Send us a message. TC BioPharm's CEO Bryan Kobel explains gamma delta t cells (GDT) in depth as well as the advantages of using GDT cells as a cell therapy vehicle. He discusses why the publicly-traded, clinical-stage cell therapy company conducts and manages all clinical trials in house as well as the unique challenges and benefits that come along with doi...

Moving On from AAV with Poseida Therapeutics' CEO, Mark Gergen 23.06.2022

We love to hear from our listeners. Send us a message. Poseida Therapeutics is a broad platform technology company led by CEO, Mark Gergen. During this episode, Gergen explains how and why the company is moving away from AAV delivery in favor of nanoparticle delivery. He shares some of the biggest hurdles the CGT sector faces when it comes to the development of off-the-shelf therapies as well as t...

Listen to the Cell & Gene: The Podcast podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.